Neosquamous epithelium does not typically arise from Barrett's epithelium

Clin Cancer Res. 2006 Mar 15;12(6):1701-6. doi: 10.1158/1078-0432.CCR-05-1810.

Abstract

Purpose: Neosquamous epithelium (NSE) can arise within Barrett's esophagus as a consequence of medical or surgical acid reduction therapy, as well as after endoscopic ablation. Morphologic studies have suggested that NSE can develop from adjacent squamous epithelium, submucosal gland ducts, or multipotent progenitor cell(s) that can give rise to either squamous or Barrett's epithelium, depending on the luminal environment. The cells responsible for Barrett's epithelium self-renewal are frequently mutated during neoplastic progression. If NSE arises from the same cells that self-renew the Barrett's epithelium, the two tissues should be clonally related and share genetic alterations; if NSE does not originate in the self-renewing Barrett's, NSE and Barrett's esophagus should be genetically independent.

Experimental design: We isolated islands of NSE and the surrounding Barrett's epithelium from 20 patients by microdissection and evaluated each tissue for genetic alterations in exon 2 of CDKN2A or exons 5 to 9 of the TP53 gene. Nine patients had p16 mutations and 11 had TP53 mutations within the Barrett's epithelium.

Results: In 1 of 20 patients, a focus of NSE had a 146 bp deletion in p16 identical to that found in surrounding Barrett's epithelium. The NSE in the remaining 19 patients was wild-type for p16 or TP53.

Conclusion: Our mutational data support the hypothesis that, in most circumstances, NSE originates in cells different from those responsible for self-renewal of Barrett's epithelium. However, in one case, NSE and Barrett's epithelium seem to have arisen from a progenitor cell that was capable of differentiating into either intestinal metaplasia or NSE.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Aged
  • Barrett Esophagus / genetics
  • Barrett Esophagus / pathology*
  • Base Sequence
  • Cyclin-Dependent Kinase Inhibitor p16 / genetics*
  • DNA Mutational Analysis
  • Epithelium / metabolism
  • Epithelium / pathology*
  • Female
  • Humans
  • Loss of Heterozygosity
  • Male
  • Microdissection
  • Mutation / genetics*
  • Tumor Suppressor Protein p53 / genetics*

Substances

  • Cyclin-Dependent Kinase Inhibitor p16
  • Tumor Suppressor Protein p53